C-Suite On Deck
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
I agree to the
terms of service
PLEASE CORRECT THE FOLLOWING:
Please Enter Some Keywords
Latham acts for Baxter on latest pharma acquisition as HSF picks up new client Claris
Herbert Smith Freehills (HSF) and Latham & Watkins won lead roles on Baxter International's acquisition of Claris Injectables for $625m, in a bid by Baxter to expand its portfolio of essential generic injectable medicines. HSF represented Claris, while Latham acted for Baxter. Baxter manufactures a broad range of essential generic injectable medications while Claris is based in India and has a 15 year history in the global injectables market. The acquisition is expected to deliver annual global revenues in excess of $100m.
I'm for real
Enter your email once to access all our information and resources.
(Your email address is required so we know you're a real person)
By downloading this content, you give permission for your contact information to be shared with the content provider who may contact you in regards to the content.